The effect of oral sucralfate on the acute proctitis associated with prostate radiotherapy: A double-blind, randomized trial

被引:37
作者
Kneebone, A
Mameghan, H
Bolin, T
Berry, M
Turner, S
Kearsley, J
Graham, P
Fisher, R
Delaney, G
机构
[1] Liverpool Hosp, Canc Therapy Ctr, Liverpool BC, NSW 1871, Australia
[2] Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia
[3] Prince Wales Hosp, Div Gastroenterol, Randwick, NSW 2031, Australia
[4] Prince Wales Hosp, Dept Radiat Oncol, Randwick, NSW 2031, Australia
[5] Westmead Hosp, Dept Radiat Oncol, Westmead, NSW, Australia
[6] St George Hosp, Canc Care Ctr, Kogarah, NSW 2217, Australia
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2001年 / 51卷 / 03期
关键词
prostate cancer; radiation proctitis; radiotherapy; sucralfate;
D O I
10.1016/S0360-3016(01)01660-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Acute rectal complications occur in the majority of patients receiving external-beam radiotherapy for carcinoma of the prostate. Sucralfate has been proposed to reduce radiation-induced mucosal injury by forming a protective barrier on ulcer bases, binding local growth factors, and stimulating angiogenesis. However, there is conflicting clinical evidence as to whether sucralfate, taken prophylactically during radiotherapy, can ameliorate the symptoms of acute radiation proctitis. Methods and Materials: A double-blind randomized trial was conducted at four Radiation Oncology Departments in Sydney, Australia, between February 1995 and June 1997. A total of 338 patients with clinically localized prostate cancer receiving small volume radiotherapy, of whom 335 were evaluable, were randomized to receive either 3 g of oral sucralfate suspension or placebo twice a day during radiotherapy. Patients kept a daily record of their bowel symptoms and were graded according to the RTOG/EORTC acute toxicity criteria. Results: One hundred sixty-four patients received sucralfate and 171 received placebo. Both groups were well balanced with regard to patient, tumor, treatment factors, and baseline symptoms, except that the placebo group had a significantly more liquid baseline stool consistency score (p = 0.004). Patients kept a daily diary of symptoms during radiotherapy. After adjusting for baseline values, there was no significant difference between the two groups with regard to stool frequency (p = 0.41), consistency (p = 0.20), flatus (p = 0.25), mucus (p = 0.54), and pain (p = 0.73). However, there was more bleeding in the sucralfate group, with 64% of patients noticing rectal bleeding, compared with 47% in the placebo group (p = 0.001). There was no significant difference between the two groups with respect to RTOG/EORTC acute toxicity (p = 0.88; sucralfate 13%, 44%, 43% and placebo 15%, 44%, 40% for grade 0, 1, and 2, respectively). Conclusion: This study suggests that oral sucralfate taken prophylactically during radiotherapy does not ameliorate the symptoms of acute radiation proctitis and may increase acute bleeding. The cause of the increased bleeding in the sucralfate group is unclear. As the pathogenesis of acute and late reactions are different, late follow-up, which includes sigmoidoscopic evaluation, is currently being performed on this cohort of patients. (C) 2001 Elsevier Science Inc.
引用
收藏
页码:628 / 635
页数:8
相关论文
共 27 条
[1]  
BOURNE R, 1987, CANCER, V60, P2195
[2]  
BROOKS WS, 1995, AM J GASTROENTEROL, V80, P206
[3]   SUCRALFATE INDUCES PROLIFERATION OF DERMAL FIBROBLASTS AND KERATINOCYTES IN CULTURE AND GRANULATION-TISSUE FORMATION IN FULL-THICKNESS SKIN WOUNDS [J].
BURCH, RM ;
MCMILLAN, BA .
AGENTS AND ACTIONS, 1991, 34 (1-2) :229-231
[4]  
De la Villa RV, 1997, AGROCHIMICA, V41, P270
[5]  
ELSAID A, 1998, P 40 ANN ASTRO M
[6]   THE EFFICACY OF SUCRALFATE SUSPENSION IN THE PREVENTION OF ORAL MUCOSITIS DUE TO RADIATION-THERAPY [J].
EPSTEIN, JB ;
WONG, FLW .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 28 (03) :693-698
[7]   EFFECTS OF SUCRALFATE ON MUCOSITIS DURING AND FOLLOWING RADIOTHERAPY OF MALIGNANCIES IN THE HEAD AND NECK REGION - A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY [J].
FRANZEN, L ;
HENRIKSSON, R ;
LITTBRAND, B ;
ZACKRISSON, B .
ACTA ONCOLOGICA, 1995, 34 (02) :219-223
[8]  
GOLDSTEIN F, 1976, AM J GASTROENTEROL, V65, P201
[9]   Blinding during data analysis and writing of manuscripts [J].
Gotzsche, PC .
CONTROLLED CLINICAL TRIALS, 1996, 17 (04) :285-290
[10]  
Hanks G E, 1992, Oncology (Williston Park), V6, P79